BioPharm International

BioPharm International magazine combines the scientific and business aspects of biopharmaceutical research, development, and production. We offer hands-on, peer-reviewed technical insights designed to help biopharmaceutical experts work more efficiently in their roles.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#867062

United States

#578572

Science and Education/Biology

#1263

Traffic sources

Monthly visitors

Articles

EMA Conditionally Authorizes Stem Cell Therapy for Blood Cancers

5 days ago | biopharminternational.com | Susan Haigney

The European Medicines Agency (EMA) announced on June 20, 2025 that it has recommended that Zemcelpro (dorocubicel/unexpanded umbilical cord cells) be granted conditional marketing authorization for the treatment of adults with hematological malignancies (blood cell cancers). Zemcelpro is used to treat patients that require allogeneic hematopoietic stem cell transplantation following chemotherapy or radiotherapy when no other type of suitable donor cells is available.
BIO 2025: Finding the Right Partner for Innovation

1 week ago | biopharminternational.com | Susan Haigney |Patrick Lavery

In BioPharm International®’s continuing conversation with Ram Aiyar, PhD, of Korro Bio, the company’s CEO and president discusses the work Korro has been doing on RNA editing for a wide range of targets, and how that research and knowledge can be brought to a wider audience of potential patients with the assistance of a major player in the biopharmaceutical industry. “That's where pharma companies really come into the picture, where it's like they are more interested.
BIO 2025: New Perspectives on RNA Editing

1 week ago | biopharminternational.com | Susan Haigney |Patrick Lavery

As the Biotechnology Innovation Organization (BIO) International Convention meets in Boston from June 16–19, 2025, BioPharm International® caught up with Ram Aiyar, PhD, CEO and president of Cambridge, Mass.-based Korro Bio. In the interview, Aiyar explains the broader implications of Korro’s OPERA platform, short for “Oligonucleotide Promoted Editing of RNA.” Increased precision, he said, is the key to addressing a broader range of diseases.
Ecolab Introduces New Bioprocessing Purification Resin at BIO 2025

1 week ago | biopharminternational.com | Susan Haigney

Ecolab Life Sciences is launching its new Purolite AP+50 affinity chromatography resin at the Biotechnology Innovation Organization (BIO) International Convention, which is being held in Boston from June 16–19, 2025. The new resin, according to a June 16, 2025 press release (1), can optimize operations during the antibody manufacturing process.
BIO 2025: Considerations for Drug Development

1 week ago | biopharminternational.com | Susan Haigney

Developing a biopharmaceutical includes multiple steps and a variety of factors that must be taken into consideration. While commercial manufacturing and tech transfer may seem far downstream in the process from development, they are actually important parts of the formulation process. “A great example is with the selection of raw materials and alignment with global compendia,” explains Robert Cornog, senior director, Product Development, at Quotient Sciences.
Biopharma Economic Development: North Carolina

1 week ago | biopharminternational.com | Susan Haigney

The biopharma industry is growing at a fast pace and doesn’t look to be slowing down. Pharmaceutical companies, therefore, are looking to contract manufacturers and biotech companies to partner with and areas in which to invest in to meet growing demand. BioPharm International® spoke with William O. Bullock, Senior VP, Economic and Statewide Development, North Carolina Biotechnology Center, about how North Carolina is meeting those demands. “[North Carolina is] really well positioned,” Bullock says.
Biopharmaceutical Development: Digitization and Cell Therapies

1 week ago | biopharminternational.com | Susan Haigney

There are a variety of new modalities in biopharmaceutical development that are influencing the overall industry. There are also new technologies, such as artificial intelligence (AI), machine learning, and digitization, that are pushing the industry into the future. But how are these new technologies impacting the development and manufacturing of cell therapies?
Advances in Digitalization and Automation of Aseptic Processing

3 weeks ago | biopharminternational.com | Cynthia Challener

As the number of biologic drugs has grown in the pharmaceutical pipeline and market, aseptic manufacturing capabilities have steadily grown in importance. Assuring sterility across many different modalities and product formats/sizes/volumes (e.g., vials, cassettes, prefilled syringes/pens, microdosing systems, intranasal delivery systems, on-body devices, bags, etc.), many of which are increasingly potent, has also become more challenging.
PCI Pharma Services Introduces New Manufacturing Facility Ahead of BIO 2025

3 weeks ago | biopharminternational.com | Patrick Lavery

PCI Pharma Services, headquartered in Philadelphia, is providing updates on its new purpose-built facility for large-scale sterile fill/finish operations at its Bedford, NH campus, which company representatives will be on hand to discuss with attendees at the Biotechnology Innovation Organization (BIO) International Convention, to be held June 16–19, 2025 in Boston (1). The 50,000-square-foot facility is expected to approach full-scale good manufacturing practice (GMP) production in summer 2025.
Therapeutic and Analytical Advancements Are Evolving Drug Substance Testing

3 weeks ago | biopharminternational.com | Patrick Lavery

June 5, 2025BioPharm InternationalBioPharm International June 2025Pages: 28–30Quality, stability, sustainability, and the increased and thoughtful integration of artificial intelligence are foremost in the minds of those on the leading edge of testing trends. Drug substance testing is a critical component of the biopharmaceutical analysis process, carrying with it inherent benchmarks of safety and efficacy that must be met.